Table 2.

Tumor Response

Tumor Response	TACE-L-P	TACE-L	P
CR	11 (17.2%)	3 (5.2%)	0.022
PR	26 (40.6%)	21 (36.2%)
SD	23 (35.9%)	23 (39.6%)
PD	4 (6.3%)	11 (19%)
ORR (CR+PR)	37 (57.8%)	24 (41.4%)	0.047
DCR (CR+PR+SD)	60 (93.7%)	47 (81.0%)	0.013

Note: Data were presented as n (%) or mean ± standard deviation.

Abbreviations: TACE-L-P, transarterial chemoembolization combined with lenvatinib and PD-(L)1 inhibitor; TACE-L, transarterial chemoembolization combined with lenvatinib; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR (CR+PR), objective response rate; DCR (CR+PR+SD), disease control rate.